Abstract:Over the past decade, significant advances have been made in the management of advanced NSCLC. The dramatic development of individualized therapies have propelled this malignance to the forefront of precision medicine. Nowadays, NSCLC has been divided into several distinct subtypes based on molecular alterations, including EGFR mutations, ALK/ROS1/NTRK translocations, and BRAFV600E mutations et al. Targeted therapy inhibiting specific actionable driver genes has resulting in a significant improvement in response rate and disease control. Targeted therapies for rare oncogenic drivers, including EGFR 20 insertions, HER2 exon 20 mutations, RET fusions, etc., are also under clinical development currently. Notably, due to low frequency of uncommon driver genes, classical randomized-controlled trial may not be the optimal approaches. Innovative biomarker-driven trials, such as Umbrella and Basket trials, may help screening patients effectively and evaluating multiple targeted drugs in matched patients. On the other hand, immune checkpoint blockades (ICBs) by inhibiting the programmed death protein 1/programmed death ligand 1 axis has yielded promising clinical responses in patients with advanced NSCLC, especially for those without EGFR/ALK aberrations. However, the response rate to ICBs is low (about 20%), mainly due to the dynamic expression of PD-L1 on tumor cells or immune cells, degree of mutational/neoantigen load, intratumoral heterogeneity, infiltrated immune cells of tumor microenvironment of NSCLC. Unlike targeted therapy, most single-gene biomarkers are not accurate for predicting ICBs efficacy and multi-omics and holistic approaches are needed. ICBs in combinations with chemotherapy, radiation therapy, or novel immunomodulatory agents are also currently being evaluated. However, the optimal order or duration of these drugs also needs further investigation. Nevertheless, there is still a lot of work to do before the era of precision medicine is truly coming.

Toward personalized treatment approaches for non-small-cell lung cancer

Future Perspectives of Precision Medicine for NSCLC

New promises and challenges in the treatment of advanced non-small-cell lung cancer

Therapeutic advances in non‐small cell lung cancer: Focus on clinical development of targeted therapy and immunotherapy

Understanding the treatment response and resistance to targeted therapies in non-small cell lung cancer: clinical insights and perspectives

The biology and management of non-small cell lung cancer

Biomarker-Targeted Therapies in Non–Small Cell Lung Cancer: Current Status and Perspectives

Targeted therapies for treatment of non-small cell lung cancer--Recent advances and future perspectives

Advancements in NSCLC: From Pathophysiological Insights to Targeted Treatments

Advances in T cells-based immunotherapy for non-small cell lung cancer

The Emerging Treatment Landscape Of Advanced Non-Small Cell Lung Cancer

Targeted therapy in advanced non-small cell lung cancer: current advances and future trends

Advancements in NSCLC

Molecular pathways, resistance mechanisms and targeted interventions in non-small-cell lung cancer

Precision medicine in non-small cell lung cancer: Current applications and future directions

The emerging treatment landscape of targeted therapy in non-small-cell lung cancer

Anti-PD-1/PD-L1 Therapy for Non-Small-Cell Lung Cancer: Toward Personalized Medicine and Combination Strategies

Promising Combinatorial Therapeutic Strategies against Non-Small Cell Lung Cancer

Frontiers of ctDNA, targeted therapies, and immunotherapy in non-small-cell lung cancer

Challenges in the Use of Targeted Therapies in Non–Small Cell Lung Cancer

Recent progress in targeted therapy for non-small cell lung cancer